Recent SEC Filing Signals

Viking's February 11 8-K said it ended 2025 with $706.0 million of cash, cash equivalents, and short-term investments. The same filing said oral VK2735 is set to enter Phase 3 in 3Q26 while the subcutaneous VANQUISH obesity program remains underway with VANQUISH-1 fully enrolled and VANQUISH-2 nearing full enrollment. A $345.0 million 2025 R&D budget is large, but the balance sheet still leaves meaningful room to carry the obesity catalyst cycle.

BridgeBio's February 24 filing reported $587.5 million of cash, cash equivalents, and marketable securities at year-end and $502.1 million of full-year 2025 revenue, including $146.0 million of net product revenue in the fourth quarter. Management also said the company added $632.5 million of 2033 convertible notes in January 2026 and highlighted three positive Phase 3 readouts in just over three months. That combination of revenue scale, financing access, and late-stage data keeps the signal skewed positive despite a $724.9 million annual net loss.

Denali reported approximately $966.2 million of cash, cash equivalents, and marketable securities in its February 26 8-K. The filing also said launch readiness is in place ahead of the April 5, 2026 PDUFA target action date for tividenofusp alfa in Hunter syndrome, while the global Phase 2/3 COMPASS study finished Cohort A enrollment in December 2025. That gives traders a real regulatory catalyst with enough liquidity to carry the commercial setup.

Dianthus used its March 9 filing to say it reached an early GO decision in the Phase 3 CAPTIVATE CIDP study after 20 confirmed responders were achieved with fewer than 40 planned Part A participants. The company also reported $514.4 million of cash, cash equivalents, and investments at December 31, 2025, which it says funds operations into 2028. A strong balance sheet plus an ahead-of-schedule Phase 3 signal is exactly the kind of filing momentum biotech traders care about.

Palvella's March 31 8-K showed pro forma cash of about $274.0 million at December 31, 2025 after reflecting roughly $215.8 million of net proceeds from its February 2026 equity financing. Management paired that financing update with positive Phase 3 SELVA topline data and plans to start a Phase 3 QTORIN rapamycin study for cutaneous venous malformations in the second half of 2026. The financing meaningfully reduces near-term balance-sheet risk while preserving a live regulatory narrative.

Xeris reported record quarterly and full-year revenue of $86.0 million and $292.0 million, respectively, in its March 2 filing. The company also guided 2026 total revenue to $375.0 million to $390.0 million and showed a roughly $0.6 million full-year GAAP net income, shifting the story from biotech burn to commercial execution. With XP-8121 headed toward Phase 3, this reads more like an operating leverage signal than a financing-risk setup.

AbCellera's February 24 filing said it had $561.0 million of cash, cash equivalents, and marketable securities plus about $135.0 million of non-dilutive government funding, for roughly $700.0 million of available liquidity. The company also reported $75.1 million of 2025 revenue and a $146.4 million net loss while advancing ABCL635 into the Phase 2 portion of a Phase 1/2 study and moving ABCL575 through Phase 1. The balance sheet is clearly supportive, but the operating profile still looks transitional rather than fully de-risked.

PDS Biotechnology reported a December 31, 2025 cash balance of $26.7 million, down from $41.7 million a year earlier, alongside a full-year net loss of about $34.5 million. Management argued that the Phase 3 amendment for VERSATILE-003 should shorten trial duration and reduce costs, but the filing still reads like a company that needs tighter spend control or fresh capital. Until the cost structure resets, the balance-sheet signal is harder to ignore than the protocol optimization story.

Aligos said in its March 5 filing that cash, cash equivalents, and investments totaled $77.8 million at year-end and should fund operations only into the third quarter of 2026. The company did complete planned HBeAg-negative enrollment in the Phase 2 B-SUPREME study of pevifoscorvir sodium, but the runway window is narrow enough that financing risk is still central to the trade. When a biotech flags less than a year of funding in the same filing as its clinical update, capital structure usually drives the tape first.

Lantern's March 30 filing reported about $10.1 million of cash, cash equivalents, and marketable securities at year-end, including roughly $4.4 million of cash and $5.7 million of marketable securities. The company said that balance funds operations only until late July to mid-September 2026 even though annual net loss narrowed to about $17.1 million and LP-184 posted a 48% clinical benefit rate at or above the therapeutic dose threshold. The science update is real, but the financing clock is even more immediate.